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Introduction
Since their initial availability 15 years ago, the thiazolidinediones (TZDs) have been widely prescribed as medication for type 2 diabetes (T2D) [1, 2] . In addition to a direct effect on insulin-regulated glucose homeostasis in vivo (i.e. reducing insulin resistance), TZD administration has been associated with an amelioration of plasma lipid profiles, fat distribution, blood pressure, inflammation, endothelial dysfunction, and atherosclerosis [2, 3] .
TZDs are agonists for the transcription factor peroxisome proliferator-activated receptorgamma (PPARγ). This nuclear receptor regulates the synthesis of proteins involved in glucose and lipid homeostasis and is mostly present in adipose tissue [4] . PPARγ, together with C/EBP, is regarded as the master regulator of fat cell differentiation. TZDs increase efficacy and kinetics of adipocyte differentiation [5, 6] and suppress TNFα-mediated inhibition of adipocyte differentiation [7, 8] . In vivo, PPARγ ablation is accompanied by an absence of all types of adipose tissue [9] , while in vitro its inactivation results in a downregulation of the expression of genes that confer the characteristics of mature adipocytes [10] . While the primary (adipogenic) action of TZDs occurs in adipose tissue, their insulin-sensitizing effects mostly take place in skeletal muscle [11] . While these two actions may seem relatively unrelated, the effects in muscle could be indirect and possibly due to a reversal of fatty acid accumulation in muscle resulting from an increased fatty acid metabolism in adipose tissue [12] . In addition, TZD-mediated PPARγ activation alters the secretion of adipokines that are involved in the regulation of insulin sensitivity and glucose metabolism (e.g. TNFα and leptin), leading to improvements in insulin action in multiple insulin-sensitive tissues [2, 6] .
In any case, it is unlikely that the low PPARγ levels in muscle and liver (10-30 times lower than in adipose tissue) are directly responsible for some of the insulin-sensitizing effects as 4 TZDs do not display insulin-sensitizing effects in mice lacking adipose tissue [13] and TZDs hardly activate PPARγ-responsive genes in muscle and liver [14] .
In insulin resistance in vivo, TZD troglitazone restores decreased GLUT4 expression levels in adipose tissue of the T2D animal model OLETF (Otsuka Long-Evans Tokushima Fatty rat) [15] . An increase in GLUT4 expression in adipocytes was also described for rosiglitazone in db/db mice [16] . However, suppression of insulin resistance in the absence of alterations in GLUT4 expression has been reported for englitazone in adipocytes of high fat diet rats [17] and for englitazone and pioglitazone in muscle of glucocorticoid-treated rats [18] . In insulin resistance in vitro, rosiglitazone has been suggested to rescue impaired glucose transport by restoring baseline levels of reactive oxygen species (ROS) [19] . However, it is not known whether and how GLUT4 is involved in this rescue. In any case, there is no report yet that describes the effects of rosiglitazone on GLUT4 in vitro.
Here, we investigated the effects of rosiglitazone on GLUT4 in (pre)adipocytes, notably its expression and cell surface levels. In addition, we examined whether the effect on cell surface amounts was specific for GLUT4 and maintained under conditions of insulin resistance. 
Cell culture
As the 3T3-L1 preadipocytes originally obtained from ATCC appeared to be very heterologous and differentiated very poorly, an individual clone of cells was isolated from these preadipocytes and tested for growth, differentiation capacity, and insulin-induced GLUT4 translocation. Cultures of this clone contained at least 95% adipocytes upon differentiation. 3T3-L1 preadipocytes were cultured, infected with retrovirus, and differentiated as described before [20] . For differentiation, preadipocytes were cultured for three days in DMEM/FBS, containing 700 nM insulin, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX), 250 nM dexamethasone, and 0.1 g/l biotin. Unless stated otherwise, preadipocytes were differentiated in the absence of rosiglitazone. Adipocytes were used for experiments 8 to 12 days after onset of differentiation, with medium changed two days prior to the experiment.
For the induction of insulin resistance, 3T3-L1 adipocytes were cultured for 24 hours in DMEM supplemented with 2 g/l BSA and 100 nM insulin [21] , followed by an extensive washing procedure, consisting of washing the wells with DMEM, supplemented with 20 mM HEPES and 2 g/l BSA, leaving the cells for 20 minutes in DMEM/HEPES/BSA, and repeating these two steps for an additional five times.
For all other experiments, cells were serum-starved for 2 hours in DMEM containing 2 g/l BSA. 7
Fluorescence-based techniques
The fluorescence-based assay for the detection of relative amounts of GLUT4 at the cell surface has been described in detail elsewhere [20] . Briefly, HA-GLUT4-expressing 3T3-L1 adipocytes grown in 96 well plates were fixed and immunolabeled using anti-HA antibody after the cells had been incubated in the absence or presence of the permeabilizing agent saponin to label GLUT4 at the cell surface or total cellular GLUT4, respectively. For microscopy, cell were incubated, fixed, and labeled as for the fluorescence-based assay.
Nuclei were stained using TOPRO3. For the quantitative detection of endogenous GLUT4
and fat droplets in differentiating cells, non-infected (pre)adipocytes were cultured in black clear-bottom well plates and labeled with anti-GLUT4 1F8 antibody and 0.1 mg/l of the lipid stain nile red (within the same wells). Both anti-GLUT4 antibody and nile red displayed negligible background levels (evident from preadipocyte cultures). For quantitative analysis, the fluorescence signal related to HA(-GLUT4), GLUT4 and nile red was measured using the bottom-reading mode in a fluorescence microtiter plate reader (FLUOstar Galaxy, BMG Labtechnologies; Offenburg, Germany). Background fluorescence (preadipocytes) was subtracted from GLUT4 and nile red measurements. For microscopy, fluorescent label was visualized using a Zeiss LSM 510 confocal laser scanning microscope (Carl Zeiss, Göttingen, Germany) in the C3M MicorBio Cell Imaging Facility.
To measure GLUT4 internalization, a method adapted from [22] was used. Adipocytes were cultured on coverslips, differentiated, serum-starved, and incubated for 20 minutes with 100 nM insulin, upon which anti-HA antibody was added to the medium. After 1 to 4 minutes, the cells were washed extensively with ice-cold PBS on ice, fixed with paraformaldehyde, permeabilized with saponin and incubated with Alexa488-conjugated goat-anti-mouse 8 antibody. Adipocytes were analyzed by epifluorescence microscopy using a 63X objective. HRP-conjugated secondary antibodies were visualized using chemiluminescence reagent (PerkinElmer) and a CCD camera-based imager (LAS-3000, Fujifilm; Tokyo, Japan).
Relative intensities were quantitated using MultiGauge software (Fujifilm).
Statistics
All data are presented as means ± SD. Experiments were repeated at least three times. 
Results

Rosiglitazone augments GLUT4 expression along adipocyte differentiation
TZDs are known for their positive effect on the differentiation of preadipocytes into adipocytes. Remarkably, a detailed analysis of the enhancement of differentiation is lacking.
To test TZD rosiglitazone in our cell system, we evaluated its effect on GLUT4 expression and lipid accumulation in 3T3-L1 (pre)adipocytes, differentiated with standard or suboptimal differentiation protocols ( A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 expression and fat accumulation was also observed when the cells were treated for various time periods with differentiation cocktail in the absence or presence of rosiglitazone (Fig. 2B ).
Exposure of differentiating preadipocytes to rosiglitazone increases cell surface GLUT4 levels in fully differentiated adipocytes
We evaluated the effect of early exposure of the cells to rosiglitazone (during differentiation)
on cell surface GLUT4 levels in fully differentiated adipocytes (Fig. 3 ). Preadipocytes expressing HA-GLUT4 were incubated with a standard differentiation cocktail in the absence or presence of rosiglitazone for 2 to 5 days and cultured further in the absence of insulin, IBMX, dexamethasone, and rosiglitazone for a total of 11 days. Adipocytes were then treated or not for 20 minutes with 100 nM insulin and cell surface GLUT4 levels were determined.
The use of rosiglitazone during the differentiation process increased cell surface GLUT4 levels in the absence of insulin for all time periods tested and also for the three day differentiation condition with insulin stimulation (Fig. 3A) . This led to a reduction in the relative effect of insulin on cell surface GLUT4 levels (Fig. 3B ).
Exposure of differentiated adipocytes to rosiglitazone increases basal cell surface GLUT4 levels and insulin sensitivity
To determine whether the effect of rosiglitazone on GLUT4 in adipocytes is restricted to its presence during the differentiation process, we differentiated 3T3-L1 preadipocytes in the absence of rosiglitazone and treated the cells with rosiglitazone after differentiation (Fig. 4 ).
This approach demonstrated that rosiglitazone gradually but largely augmented cell surface GLUT4 levels after up to five days of treatment (Fig. 4A) . In contrast, cell surface GLUT4 12 levels after acute insulin stimulation were comparable between control and rosiglitazonetreated adipocytes (Fig. 4A) . Fluorescence confocal microscopy of control and rosiglitazonetreated adipocytes confirmed these results (Fig. 4B) . Moreover, this increase in cell surface GLUT4 levels in basal but not insulin-stimulated cells was paralleled by increases in basal glucose uptake and an absence of increased glucose uptake under conditions where the cells were stimulated with high concentrations of insulin (Fig. 4C) . Cells that were stimulated with submaximal concentrations of insulin (1 nM) still displayed a rosiglitazone-induced augmentation of glucose uptake. Western blot analysis of rosiglitazone-treated cells revealed that the increase in glucose uptake could not be accounted for by an increase in GLUT4
expression. However, in accordance with previous studies [23] , rosiglitazone increased the expression of the insulin receptor ( Fig. 4D, E) . The increase in cell surface GLUT4 levels was not specific to rosiglitazone as other TZD family members, pioglitazone and troglitazone, also displayed similar effects on GLUT4 (Fig. 4F ).
Treatment of differentiated adipocytes for five days with various concentrations of rosiglitazone resulted in a dose response curve for cell surface GLUT4 expression with an EC50 value of 22 nM and maximum effects at 0.5 μM (Fig. 5A ). This response was highly similar to that of preadipocytes regarding their rosiglitazone-enhanced differentiation ( 
The effect of rosiglitazone on basal cell surface GLUT4 levels is long-lasting
We next addressed the question whether rosiglitazone treatment of adipocytes induced a temporary effect on GLUT4 or whether this was a long-term (lasting) effect. Adipocytes were treated with rosiglitazone at various time periods before the analysis of cell surface GLUT4 levels, as indicated in Fig. 6A . Unfortunately, culturing the adipocytes for extended periods increased basal cell surface levels, even in the absence of rosiglitazone. Nevertheless, our study revealed that a 5 day rosiglitazone treatment followed by a rosiglitazone-free incubation period of 8 days was not different from a rosiglitazone treatment during the final 5 days (Fig.   6B ). This indicates that the effect of rosiglitazone on GLUT4 is long-lasting (irreversible during the time course of the experiment), likely due to a change in cell properties.
Rosiglitazone also increases cell surface levels of the transferrin receptor
To test whether the effect of rosiglitazone treatment is specific for GLUT4, we studied its effect on the transferrin receptor (TfR) (Fig. 7) . While only ~50% of the intracellular GLUT4 pool is present in endosomes, cytoplasmic TfR is present exclusively in endosomes and therefore marks a subpopulation of the intracellular GLUT4-containing compartments [24] .
To compare the TfR with GLUT4 using similar methodologies, we studied a TfR that was extracellularly tagged with an HA epitope. Immunofluorescence microscopy demonstrated that the localization of the tagged TfR was similar to the localization of endogenous TfR (Suppl. fig. S1 ). A quantitative analysis demonstrated that the TfR displayed quite a remarkable insulin-responsiveness (Fig. 7A) . Though less pronounced than for GLUT4, the TfR translocated towards the cell surface in response to insulin. Similarly to GLUT4, the amount of TfR at the cell surface augmented with rosiglitazone ( Fig. 7B) , while the effects of A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 rosiglitazone and insulin were not additive, indicating that the effect of rosiglitazone is not specific to GLUT4 and that rosiglitazone may augment endosomal recycling kinetics.
Rosiglitazone does not affect GLUT4 internalization
As rosiglitazone affects both GLUT4 and TfR, it is tempting to speculate that rosiglitazone alters cell surface GLUT4 levels by acting on its internalization rate. To test this possibility, adipocytes were incubated for 5 days in the presence or absence of 10 μM rosiglitazone and internalization was measured (Fig. 8 ). Cells were incubated with anti-HA antibody for very short time periods to ensure that anti-HA-bound GLUT4 did not yet return to the cell surface after its internalization. Next, the percentage of cells with internalized label was determined.
This revealed that rosiglitazone did not inhibit GLUT4 internalization, indicating that another step in the intracellular trafficking of GLUT4 (and of TfR) is altered by rosiglitazone.
Rosiglitazone restores insulin-induced GLUT4 translocation in adipocytes that are rendered insulin-resistant in vitro
TZDs have been studied for their potency in reversing insulin resistance in 3T3-L1 adipocytes. However, these studies have focused on the reversal of the reduction in insulininduced glucose uptake. Hence, it remains uncertain whether the TZD effects on insulin resistance can be accounted for by a change in the cellular expression of GLUT4, by an increase in cell surface GLUT4 levels, or by another mechanism. Therefore, we addressed the question whether rosiglitazone pretreatment could prevent the relative decrease in cell surface GLUT4 levels induced by a 24 hour insulin treatment (Fig. 9 ). This treatment clearly induced insulin resistance as a subsequent 20 minute stimulation of the cells with 1, 10, and 100 nM A c c e p t e d M a n u s c r i p t   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   15 insulin resulted in reduced cell surface GLUT4 levels compared to control cells (Fig. 9A) .
However, in rosiglitazone-treated adipocytes, acute insulin-induced GLUT4 translocation was not impaired by a 24 hour insulin pretreatment. As the insulin effects in rosiglitazone-treated cells are smaller compared to non-treated cells, we also examined the effects of shorter rosiglitazone treatments on reduced cell surface GLUT4 levels (Fig. 9B) . This demonstrated that after two days of treatment, rosiglitazone completely restored acute insulin responsiveness of GLUT4 translocation in cells subjected to a 24 hour insulin incubation, without largely enhancing basal cell surface levels. These data indicate that rosiglitazone augments basal cell surface GLUT4 levels and independently restores the response of GLUT4 to insulin stimulation under conditions that induce insulin resistance. To evaluate whether rosiglitazone rescues the decrease in GLUT4 expression that has been associated with insulin resistance in vivo and in vitro [21, 25] , we treated adipocytes for three days with or without insulin and rosiglitazone. This demonstrated that the insulin-induced downregulation of GLUT4 expression (~50% after three days) is not rescued by rosiglitazone (Fig. 9C) .
Furthermore, our studies demonstrated that reductions in GLUT4 expression due to TNF-α treatment are not rescued by rosiglitazone either (data not shown).
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Discussion
While adipose tissue is not the main storage site for glucose in the postprandial state, glucose metabolism in this organ is essential for whole body glucose homeostasis, via a direct regulation of the synthesis and secretion of adipokines that have important effects in other parts of the body. Adipocyte-specific knock-out of GLUT4 results in insulin resistance in muscle and liver and an enhanced secretion of adipokines, amongst which serum retinol binding protein 4 (RBP4) [26, 27] . RBP4 levels have been demonstrated to be elevated in insulin resistance and T2D. Moreover, its overexpression causes insulin resistance while its genetic deletion enhances insulin sensitivity. Interestingly, rosiglitazone has been shown to restore serum RBP4 levels in insulin resistant mice [27] . Given that both GLUT4 and rosiglitazone regulate adipokine secretion, adipocytic GLUT4 could very well be implicated in the rosiglitazone-induced adipokine-dependent amelioration of whole body glucose homeostasis in T2D.
Our results support this hypothesis as they show that rosiglitazone increases basal cell surface GLUT4 levels and glucose uptake by adipocytes. In addition to its enhancement of GLUT4 expression throughout adipocyte differentiation, this TZD augmented the amount of GLUT4
at the plasma membrane of adipocytes when administered either during (pre)adipocyte differentiation or afterwards. So, even while the time-scale of the effect of insulin and rosiglitazone on GLUT4 traffic are distinct, rosiglitazone clearly partially mimics insulin action. Moreover, even when administered after the cells had been fully differentiated, its effect on GLUT4 was irreversible, suggesting that rosiglitazone changes adipocyte properties.
Possibly, rosiglitazone, via its interaction with transcription factor PPARγ, may change the expression of one or several proteins that play a regulatory role in endosomal recycling such as rab, SNARE, or sorting nexin proteins [28, 29] . In support of this, the rosiglitazoneinduced effects on GLUT4 required several days of treatment. In contrast, troglitazone has been shown to largely alter cell surface GLUT4 levels in muscle and fat cells within 15 and 24 hours of treatment, respectively [30, 31] . Troglitazone concentrations that were found to increase cell surface GLUT4 levels in these studies were much higher than the concentrations of rosiglitazone we found to be effective, but this correlates well with the lower affinity of troglitazone for PPARγ [32, 33] . Neither in muscle cells [30] nor in adipocytes [31, 34] (Fig.   3A , C) were the effects of glitazones and high concentrations of insulin additive. However, rosiglitazone treatment of ob/ob mice has been reported to increase glucose uptake and cell surface GLUT4 levels in primary adipocytes stimulated with insulin ex vivo, but this was most probably due to an increase in GLUT4 expression [16] . Basal cell surface GLUT4 levels were found to be increased by troglitazone in L6 muscle cells [30] and primary adipocytes [31] , and by rosiglitazone and troglitazone in 3T3-L1 adipocytes (this study). Furthermore, troglitazone was found to induce a significant (50%) increase in GLUT4 expression levels in adipocytes [31] , while this was not the case for rosiglitazone in our studies.
Our studies have suggested that the effect of rosiglitazone is not specific for GLUT4, as rosiglitazone also increased basal but not insulin-enhanced cell surface levels of the transferrin receptor (TfR). The predominantly endosome-localized TfR is constitutively recycling towards the plasma membrane, while its recycling kinetics are increased even further upon acute insulin stimulation [35] . As both GLUT4 and TfR surface levels are increased upon rosiglitazone treatment, we propose that rosiglitazone increases endosomal recycling kinetics. For GLUT4 this increase is quite dramatic, as GLUT4 recycles extremely slowly in non-stimulated cells [36, 37] . As the rosiglitazone effects appear not to be further enhanced by insulin, similar molecular systems involved in endosomal recycling may be 18 implicated in the long-term rosiglitazone effects and in acute insulin action. The rosiglitazoneinduced increase in the expression of the insulin receptor (Fig. 3D) could imply an activation of the insulin signaling cascade under basal conditions. However, neither the insulin receptor nor its downstream effector Akt were phosphorylated under basal conditions in rosiglitazonetreated adipocytes (data not shown). Our data demonstrate that the increase in cell surface GLUT4 levels is not due to changes in its internalization rate. In contrast, metformin has been demonstrated to inhibit GLUT4 endocytosis and thereby to augment insulin-induced increases in the amount of GLUT4 at the plasma membrane [38] , which is clearly different from our findings. Since rosiglitazone, as well as other TZDs, affect the synthesis and secretion of adipokine/cytokines, such as adiponectin [39] , RBP4 [27] , leptin [40] , Il-6 [41] , and TNF-α [42] , it cannot be excluded that the effect on endosomal recycling is mediated in part via an alteration in adipokine secretion (autocrine effect). Alternatively, this effect on endocytic recycling could be mediated (in part) via annexin II, which is involved in insulin-induced GLUT4 translocation, and whose expression levels are elevated upon troglitazone treatment [34] . Finally, TZDs might enhance endosomal recycling via altering intracellular ROS (reactive oxygen species) levels, as TZDs have been shown to display antioxidant properties [19] .
These antioxidant properties may also be implicated in the effects of rosiglitazone on GLUT4 in insulin resistance. Previously, the reduction in glucose uptake in insulin-resistant 3T3-L1 adipocytes has been shown to be suppressed by ROS scavenger MnTBAP as well as by rosiglitazone, while rosiglitazone decreased intracellular ROS as effectively as MnTBAP [8, 19] . However, it is unclear whether the TZD-mediated restoration of glucose uptake was mediated via a change in glucose transporter expression level or via restoration of the rate of insulin-induced GLUT4 translocation. Our studies indicate that rosiglitazone completely 19 restores the response of GLUT4 to insulin stimulation under conditions that normally induce insulin resistance. This was already evident after two days of rosiglitazone treatment, before major changes in basal cell surface GLUT4 levels occurred. This effect is likely to be mediated via a restoration of insulin signaling [43] and possibly due to an increase in the expression of the insulin receptor (Fig. 3) . It has been reported that in primary adipocytes from rosiglitazone-treated ob/ob mice GLUT4 expression is increased, concurrent with an increase in cell surface GLUT4 levels under conditions of insulin stimulation [16] . However, our studies have demonstrated that the reduction in GLUT4 expression that is associated with insulin resistance is not reversed by rosiglitazone, suggesting that at least in adipocytes rendered insulin-resistant in vitro, rosiglitazone acts mainly on GLUT4 translocation and not on GLUT4 expression.
In conclusion, using the 3T3-L1 adipocyte cell model, we have investigated for the first time the effects of rosiglitazone on GLUT4 in vitro and have demonstrated that treatment of adipocytes for several days with rosiglitazone results in an irreversible effect on endosomal protein traffic, in an augmentation of GLUT4 at the PM, and in an increased glucose uptake.
A second, independent effect of rosiglitazone was seen in insulin resistant cells, where it fully restored insulin-induced GLUT4 translocation. While it remains to be determined by which molecular mechanisms rosiglitazone affects endosomal GLUT4 recycling and GLUT4
insulin-sensitivity in insulin resistance, these effects are likely to contribute to the rosiglitazone-mediated enhancement of glucose homeostasis in vivo.
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Figure legends Adipocytes cultured in 96 well plates were treated and labeled as described for (A), but fluorescence was quantified using a fluorescence microtiter plate reader. Each well was used for both GLUT4 and lipid measurements. The amount of GLUT4 and lipid in adipocytes differentiated using the standard differentiation protocol (700 nM insulin, 500 μM IBMX, and 250 nM dexamethasone) was set to 100%. Note that rosiglitazone increased GLUT4 expression and lipid accumulation by enhancing the effects of IBMX and/or dexamethasone.
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